HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
BASEL, Switzerland, Jan. 21, 2016 -- GSK (GlaxoSmithKline) informed Basilea today that it has elected to discontinue its U.S. alitretinoin program. Global rights to Toctino (alitretinoin) were transferred to Stiefel, a GSK company, in July 2012. Basilea has the option to re-acquire the U.S. alitretinoin rights. GSK continues to commercialize Toctino in its current markets.
About Basilea
Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
| Media Relations | Investor Relations |
|
Peer Nils Schröder, PhD Head Public Relations & Corporate Communications +41 61 606 1102 [email protected] |
Barbara Zink, PhD, MBA Head Corporate Development +41 61 606 1233 [email protected] |
This press release can be downloaded from www.basilea.com.
Press release (PDF) http://hugin.info/134390/R/1980584/725577.pdf
HUG#1980584
